FDA warning letter · #716505
eDrugstore: What the FDA Letter Means for What You Pay
Operating
marketing / labeling
September 2025
Not logged
Primary source
Read the original letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/edrugstore-716505-09092025
What FDA cited
Quoted verbatim from the letter dated
Read the full letter →This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.edrugstore.com in August 2025 and has observed that your website offers various compounded drug products, including tirzepatide.
- 1
“"FDA-Approved Active"”
- 2
“"eDrugstore guarantees that all Tirzepatide medications are genuine, FDA-approved formulations for maximum efficacy and safety."”
- 3
“"Tirzepatide (Zepbound)…."”
- 4
“Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”
Process
How a warning letter proceeds
- 1
Letter issued
September 2025
- 2
15-working-day response window
FDA gives the company 15 working days to respond in writing.
- 3
Close-out, if issued
FDA may post one once it is satisfied the cited issues have been corrected.
Is eDrugstore still operating?
edrugstore.com returned a live storefront when we checked in August 2026, with a weight-loss category listed alongside an extensive erectile-dysfunction catalogue and an affiliate sign-in in the site header.
What this means for what you pay
Of all the wording FDA quoted across this roster, the phrase used here is the one a price shopper is most likely to be reassured by and least able to check: a guarantee that the medication is a genuine, FDA-approved formulation. A compounded drug is by definition not an FDA-approved drug — that is the structural point, and it does not depend on anything about this seller's quality. The practical takeaway is narrow and useful: an "FDA-approved" badge next to a compounded product's price is not a claim about that product's regulatory status, and FDA said as much in writing here. It is also worth knowing that the letter and the Healthy Male letter issued the same day print the same Tempe, Arizona address, so a shopper comparing the two sites is not necessarily comparing two independent operations.
Has eDrugstore responded?
As of , FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence eDrugstore failed to respond.
Sources
Other letters in this index
Maximus
marketing / labeling · Issued June 2026
Ezra
marketing / labeling · Issued June 2026
Eden
marketing / labeling · Issued June 2026
Joi + Blokes
marketing / labeling · Issued June 2026
Thrivelab
marketing / labeling · Issued June 2026
MEDVi
marketing / labeling · Issued February 2026
Editorial disclaimer: An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.